Pelthos Therapeutics Inc. (PTHS)
Pelthos Therapeutics Inc. operates as a biopharmaceutical enterprise dedicated to developing and commercializing innovative medical treatments that address significant, unmet patient needs. Its primary offerings include ZELSUVMI, a medication specifically indicated for the treatment of molluscum contagiosum in individuals aged one year and older. Furthermore, the company leverages NITRICIL, an exclusive technological platform grounded in nitric oxide research. Established in 2002, this Durham, North Carolina-based firm was previously known as Channel Therapeutics Corporation, before rebranding to Pelthos Therapeutics Inc. in July 2025.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
Pelthos Therapeutics Inc.
NYSE:PTHSHealthcare · Biotechnology
-13.22%$17.00
Mkt Cap$65.08M
Float1.39M
O/S3.83M
Inst Own34.6%
SI7.5%
Dilution
Delisting Issues Timeline
Financials Summary
Revenue$16.8M
Net Income-$43.32M
Total Assets$130.4M
Free Cash Flow-$22.69M
Debt & Equity
Debt 47%
Equity 53%
Total Debt$34.83M
Total Equity$38.88M
Shares Outstanding
Short Interest
Split History
No splits on record
Nothing in PTHS's public trading history: no forward or reverse split has affected the share count.
Balance Sheet Details
Assets$130.4M
Liabilities$91.52M
Accounts Receivable$8.86M
Accounts Payable$2.99M
Inventory$23.57M
PP&E (Net)$12.84M
Goodwill$24.68M
Intangible Assets$39.47M
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Revenue | $16.8M | $0 | $0 | $0 | $0 | $200K |
| YoY Growth | - | - | - | - | - | - |
| Cost of Revenue | $9.37M | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | $7.43M | $0 | $0 | $0 | $0 | $200K |
| Gross Margin | 44.2% | - | - | - | - | 100.0% |
| Research and Development | $1.23M | $1.18M | $2.58M | $392K | $209K | $139K |
| Selling, General, and Administrative | $37.08M | $6.39M | $4.28M | $1.93M | $630K | $1.42M |
| Other | $1.56M | $0 | $0 | $0 | $0 | $0 |
| Total Operating Expenses | $39.86M | $7.57M | $6.86M | $2.32M | $839K | $1.55M |
| Operating Income (EBIT) | -$32.43M | -$7.57M | -$6.86M | -$2.32M | -$839K | -$1.35M |
| Operating Margin | -193.1% | - | - | - | - | -677.2% |
| Interest Expense | $3.01M | $786K | $519K | $140K | $253 | $2K |
| Interest Income | $5K | $0 | $0 | $0 | $0 | $0 |
| Other Income (Expense) | -$18.28M | -$384K | -$519K | -$140K | $244K | $693K |
| Income Before Tax (EBT) | -$50.71M | -$7.96M | -$7.38M | -$2.46M | -$595K | -$661K |
| Income Tax Expense | -$7.39M | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$43.32M | -$7.96M | -$7.38M | -$2.46M | -$595K | -$661K |
| Net Income Margin | -257.9% | - | - | - | - | -330.4% |
| Supplementary Data | ||||||
| EPS | -23.04 | -13.54 | -12.80 | -4.26 | -1.00 | -1.15 |
| Diluted EPS | -23.04 | -13.54 | -12.80 | -4.26 | -1.00 | -1.15 |
| Weighted Average OS | 1.88M | 587,620 | 576,752 | 576,752 | 576,752 | 576,752 |
| EBITDA | -$45.41M | -$7.17M | -$6.86M | -$2.32M | -$595K | -$659K |
| EBITDA Margin | -270.4% | - | - | - | - | -329.6% |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Currency | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
| Assets | ||||
| Current Assets | ||||
| Cash and Cash Equivalents | $18.02M | $513K | $96K | $55K |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Cash and Short-Term Investments | $18.02M | $513K | $96K | $55K |
| Accounts Receivable | $8.86M | $40K | $0 | $0 |
| Inventory | $23.57M | $0 | $0 | $0 |
| Other Current Assets | $419K | $750K | $0 | $0 |
| Total Current Assets | $52.7M | $1.37M | $96K | $55K |
| Long-Term Assets | ||||
| Property, Plant & Equipment Net | $12.84M | $0 | $0 | $0 |
| Goodwill | $24.68M | $0 | $0 | $0 |
| Intangible Assets | $39.47M | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Deferred Tax Assets | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $711K | $0 | $0 | $0 |
| Total Long-Term Assets | $77.7M | $0 | $0 | $0 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $130.4M | $1.37M | $96K | $55K |
| Liabilities | ||||
| Current Liabilities | ||||
| Accounts Payable | $2.99M | $1.9M | $4.62M | $2.99M |
| Short-Term Debt | $635K | $2.19M | $1.27M | $540K |
| Current Income Tax Payable | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $966K | $0 | $0 | $0 |
| Other Current Liabilities | $21.41M | $0 | $646K | $222K |
| Total Current Liabilities | $25.99M | $4.08M | $6.54M | $3.76M |
| Long-Term Liabilities | ||||
| Long-Term Debt | $31.44M | $0 | $0 | $0 |
| Long-Term Unearned Revenue | $1.28M | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $30.05M | $0 | $0 | $0 |
| Total Long-Term Liabilities | $65.52M | $0 | $0 | $0 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Total Liabilities | $91.52M | $4.08M | $6.54M | $3.76M |
| Stockholders' Equity | ||||
| Preferred Stock | $0 | $0 | $60 | $60 |
| Common Stock | $0 | $613 | $391 | $111 |
| Retained Earnings | -$64.79M | -$21.47M | -$13.52M | -$6.14M |
| Comprehensive Income & Other | $0 | $0 | $0 | $0 |
| Other Stockholders' Equity | $103.67M | $18.76M | $7.07M | $2.43M |
| Total Equity | $38.88M | -$2.71M | -$6.44M | -$3.71M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $130.4M | $1.37M | $96K | $55K |
| Supplementary Data | ||||
| Total Debt | $34.83M | $2.19M | $1.27M | $540K |
| Net Debt | $16.8M | $1.67M | $1.17M | $485K |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Currency | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
| Operating Activities | ||||
| Net Income | -$43.32M | -$7.96M | -$7.38M | -$2.46M |
| Depreciation & Amortization | $2.29M | $0 | $0 | $0 |
| Deferred Income Tax | $0 | $0 | $0 | $0 |
| Stock-Based Compensation | $0 | $1.8M | $1.73M | $110K |
| Changes in Working Capital: | ||||
| Accounts Receivable | -$8.81M | -$46K | $0 | $0 |
| Inventory | $1.78M | $0 | $0 | $0 |
| Accounts Payable | $1.36M | $1.18M | $1.63M | $414K |
| Other Working Capital | -$395K | -$1.1M | $424K | $227K |
| Total Working Capital Change | -$6.07M | $35K | $2.05M | $641K |
| Other Non-Cash Items | $24.52M | $329K | $2.62M | $140K |
| Net Cash from Operating | -$22.59M | -$5.79M | -$981K | -$1.57M |
| Investing Activities | ||||
| Capital Expenditures | -$99K | $0 | $0 | $0 |
| Acquisitions | -$5.14M | $0 | $0 | $0 |
| Purchases of Investments | $0 | $0 | $0 | $0 |
| Sales of Investments | $0 | $0 | $0 | $0 |
| Other Investing Activities | $0 | $0 | $0 | $0 |
| Net Cash from Investing | -$5.24M | $0 | $0 | $0 |
| Financing Activities | ||||
| Debt Repaid | -$17.9M | - | - | - |
| Common Stock Issuance | $27.59M | $6.05M | $255K | $0 |
| Common Stock Repurchases | $0 | -$167K | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Financing Activities | $0 | $0 | $0 | $1.22M |
| Net Cash from Financing | $45.34M | $6.21M | $1.02M | $1.62M |
| Forex Effect | -$443 | $0 | $0 | $0 |
| Net Change in Cash | $17.51M | $417K | $41K | $55K |
| Supplementary Data | ||||
| Operating Cash Flow | -$22.59M | -$5.79M | -$981K | -$1.57M |
| Capital Expenditure | -$99K | $0 | $0 | $0 |
| Free Cash Flow | -$22.69M | -$5.79M | -$981K | -$1.57M |
| Cash at Beginning | $513K | $96K | $55K | $0 |
| Cash at End | $18.02M | $513K | $96K | $55K |